Group items tagged

The Fiscal Year 2015 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP): Alcohol and Substance Abuse Research Program - $4.0 million Amyotrophic Lateral Sclerosis Research Program - $7.5 million Autism Research Program - $6.0 million Bone Marrow Failure Research Program - $3.2 million Breast Cancer Research Program - $120.0 million Duchenne Muscular Dystrophy Research Program - $3.2 million Epilepsy Research Program - $7.5 million Gulf War Illness Research Program - $20.0 million Joint Warfighter Medical Research Program - $50.0 million Lung Cancer Research Program - $10.5 million Military Burn Research Program - $8.0 million Multiple Sclerosis Research Program - $5.0 million Neurofibromatosis Research Program - $15.0 million Neurotoxin Exposure Treatment Parkinson's Research Program - $16.0 million Orthotics and Prosthetics Outcomes - $10.0 million Ovarian Cancer Research Program - $20.0 million Peer Reviewed Alzheimer's Research Program - $12.0 million Peer Reviewed Cancer Research Program - $50.0 million Peer Reviewed Medical Research Program - $247.5 million Peer Reviewed Orthopaedic Research Program - $30.0 million Prostate Cancer Research Program - $80.0 million Spinal Cord Injury Research Program - $30.0 million Tuberous Sclerosis Complex Research Program - $6.0 million Vision Research Program - $10.0 million

The Amyloidosis Foundation focuses on raising awareness in the medical field of amyloidosis, a group of diseases in which abnormal protein, known as amyloid fibrils, builds up in tissue; educating medical professionals through its Grand Rounds program and attendance at medical conferences; prioritizing a research agenda through grants and partnership with the Amyloidosis Research Consortium; and empowering patients through its comprehensive range of services, including accurate, up-to-date information.

The Klarman Family Foundation is interested in providing strategic investment in translational research that will accelerate progress in developing effective treatments for anorexia nervosa, bulimia nervosa and binge eating disorder. The Program's short-term goal is to support the most outstanding science and expand the pool of scientists whose research explores the basic biology of feeding, anorexia nervosa, bulimia nervosa, and/or binge eating disorder. The long-term goal is to improve the lives of patients suffering from these conditions. Examples of funding areas include but are not limited to molecular genetic analysis of relevant neural circuit assembly and function; genetic and epigenetic research; animal models created by genetically altering neural circuits; and testing of new chemical entities that might be used in animal models as exploratory treatments.  Please note that imaging studies involving humans are not eligible. Investigators conducting research in the neuro-circuitry of fear conditioning or reward behavior may also apply but must justify the relevance of their research projects to the basic biology of eating disorders. Clinical psychotherapeutic studies, medication trials and research in the medical complications of these disorders are outside the scope of this Program.

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine Development * Molecular Epidimiology * Imaging * Disease Modeling

Biophotonics applies photonics technology to the fields of medicine, biology and biotechnology.  Basic research and innovation in photonics that is very fundamental in science and engineering is needed to lay the foundation for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies.  Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening.  Low cost and minimally invasive medical diagnostics and therapies are key goals. Examples of topics are: Macromolecule Markers - Innovative methods for labeling of macromolecules, new compositions of matter/methods of fabrication of multi-color probes such as might be used for marking and detection of specific pathological cells and push the envelope of optical sensing to the limits of detection, resolution, and identification Low Coherence Sensing at the Nanoscale - Low coherence enhanced backscattering (LEBS), n-dimensional elastic light scattering, and angle-resolved low coherence interferometry for early cancer detection (dysplasia) Neurophotonics - Studies of photon activation of neurons at the interface of nanomaterials attached to cells.  Development and application of biocompatible photonic tools such as parallel interfaces and interconnects for communicating and control of neural networks Micro- and Nano-photonic - Development and application of nanoparticle fluorescent quantum-dots; sensitive, multiplexed, high-throughput characterization of macromolecular properties of cells; nanomaterials and nanodevices for biomedicine Optogenetics - Employing light-activated channels and enzymes for manipulation of neural activity with temporal precision. 

Applicants must choose one of the following categories they feel their project best exemplifies: 1.) Outstanding Emerging Innovation: The winning nominee is a person or company working on the basic research phase of an innovation - for three years or less, pre-commercialization - that has received grant money or outside money and that demonstrates the potential for continued growth and success. 2.) Outstanding Bioscience Innovation: The winning nominee is a company that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenetics. 3.) Outstanding Information Technology Innovation: The winning nominee is a company that has achieved a significant milestone in information technology, including hardware and software, packaged applications, custom applications and digital media. 4.) Outstanding Marketing Innovation: The winning nominee is a company that has achieved a significant milestone in consumer marketing. 5.) Outstanding Advanced Engineering Innovation: The winning nominee is a company that has achieved a significant milestone in advanced engineering - where technology is used to design a product.

Biophotonics applies photonics technology to the fields of medicine, biology and biotechnology.  Basic research and innovation in photonics that is very fundamental in science and engineering is needed to lay the foundation for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies.  Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening.  Low cost and minimally invasive medical diagnostics and therapies are key goals. Examples of topics are: Macromolecule Markers - Innovative methods for labeling of macromolecules, new compositions of matter/methods of fabrication of multi-color probes such as might be used for marking and detection of specific pathological cells and push the envelope of optical sensing to the limits of detection, resolution, and identification Low Coherence Sensing at the Nanoscale - Low coherence enhanced backscattering (LEBS), n-dimensional elastic light scattering, and angle-resolved low coherence interferometry for early cancer detection (dysplasia) Neurophotonics - Studies of photon activation of neurons at the interface of nanomaterials attached to cells.  Development and application of biocompatible photonic tools such as parallel interfaces and interconnects for communicating and control of neural networks Micro- and Nano-photonic - Development and application of nanoparticle fluorescent quantum-dots; sensitive, multiplexed, high-throughput characterization of macromolecular properties of cells; nanomaterials and nanodevices for biomedicine Optogenetics - Employing light-activated channels and enzymes for manipulation of neural activity with temporal precision. 

The Summer Undergraduate Research Fellowship (SURF) Program at Cincinnati Children's Hospital Medical Center offers undergraduates the chance to explore clinical and basic science research in laboratories in the Department of Pediatrics, University of Cincinnati College of Medicine. The primary goal is to provide students with a foundation for making career choices in the biomedical sciences. Students have the opportunity to work with one of more than 700 faculty members at Cincinnati Children's Hospital Medical Center, many of whom have active research programs that cover all areas of pediatric medicine, including the study of developmental biology, congenital disorders, genetic diseases, cancer, cardiology, neurology and immunology.

The SCIMS program is designed to provide a multidisciplinary system of rehabilitation care specifically to meet the needs of individuals with SCI. To be eligible for a SCI Model Systems grant, an applicant institution must encompass a continuum of care for people with SCI, including emergency medical services, acute care services, acute medical rehabilitation services, and post-acute services. For purposes of this program, SCI is defined as a clinically discernible degree of neurologic impairment of the spinal cord following a traumatic event. NIDILRR currently supports 14 SCIMS centers through this program. The funding for these Centers is primarily used to conduct SCI research and to collect and send data to the SCIMS longitudinal database. SCIMS Centers will be funded at varying amounts up to the maximum award based on the numbers of subjects eligible for follow-up in the existing SCIMS longitudinal database. Existing centers with significantly larger numbers of subjects will receive higher funding within the specified range, as determined by NIDILRR after the applicant is selected for funding. Applicants provide detailed budgets for each research project and for data collection costs associated with the longitudinal database. Funding will be determined individually for each successful applicant, up to the maximum allowed, based upon the documented workload associated with the follow-up data collection, the other costs of the grant, and the overall budgetary limits of the program

The Purpose of this FOA is to solicit cooperative agreement applications that propose clinical trials to establish the effectiveness of existing therapies and approaches for prevention and management of pain. The studies must address questions within the mission and research interests of participating NIH Institutes and Centers and evaluate preventive strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, diagnostic testing, behavioral change, rehabilitation strategies, complementary therapies, integrated approaches, and delivery system strategies in well controlled trials The overall goal is to inform clinicians about the effectiveness of interventions that will improve functional outcomes and reduce pain across the continuum of acute to chronic pain associated with many types of diseases or conditions or pain presenting as a disease itself. Clinical trials will be conducted within the infrastructure of the HEAL Pain Management Effectiveness Research Network.

The intent of this award is to fund an organization that can provide collaborative research assistance under three research focus areas:1) undersea medicine research, 2) regenerative medicine research and 3) neurotrauma research. The award will be issued as a cooperative agreement between the recipient and the Government (OUMD-NMRC (Operational and Undersea Medicine Directorate at Naval Medical Research Center)). The award recipient (awardee) will collaborate with OUMD-NMRC to develop and implement scientific research efforts and share substantial programmatic involvement with OUMD-NMRC.

The world needs more effective, functional and affordable technology solutions to clinical medical problems. With the BMEidea competition, the nation's leading competition for biomedical and bioengineering students, we challenge students to pioneer a health-related technology that addresses a real clinical need. Competition entries are judged on: Technical, economic and regulatory feasibility Contribution to human health and quality of life Technological innovation Potential for commercialization Strong BMEidea submissions define a problem and demonstrate the development of a device, product, or technology designed to solve it. BMEidea awards are presented each year at the MD&M East Medical Device Trade Show and Convention. Competition winners will receive cash awards as well as access to resources to be used for further development and commercialization of their products. In addition, the first place institution will get to display the BMEidea trophy in their winning department for the year.

Applications to the Fiscal Year 2017 (FY17) Neurofibromatosis Research Program (NFRP) are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA). The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The NFRP was initiated in 1996 to provide support for research of exceptional scientific merit that promotes the understanding, diagnosis, and treatment of neurofibromatosis (NF) including NF type 1 (NF1) and type 2 (NF2) and schwannomatosis.

Applications to the Fiscal Year 2017 (FY17) Neurofibromatosis Research Program (NFRP) are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA). The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The NFRP was initiated in 1996 to provide support for research of exceptional scientific merit that promotes the understanding, diagnosis, and treatment of neurofibromatosis (NF) including NF type 1 (NF1) and type 2 (NF2) and schwannomatosis.

NIFA requests applications for the Mental Health Research Project (MHRP) for the fiscal year FY 2017 to support the Air Force Medical Operations Agency (AFMOA) MHRP in promoting the psychological health and well being for Airmen and there families through staff development, consultation, program and resource development; program evaluation, and data tracking.The primary objective for this project is to assess, develop, and evaluate programming to treat and prevent mental health problems to support the Mental Health Division of the Air Force Medical Operations Agency (AFMOA).This work also supports the mission of the DoD-USDA Partnership for Military Families Memorandum of Understanding (MOU) signed in 2010 by NIFA and DoD senior leadership. The goal of the MOU is "…to enhance federal interagency coordination and build capacity for partnerships and collaboration among the agencies and across public and private sectors to sustain programs and services for military service members and their families."

There is a global trend in the rise of HIV among older adults. In 2013, an estimated 42% of Americans living with HIV were at least 50 years old, 25% were at least 55 years old, and 6% were at least 65 years old. Since the advent of combination antiretroviral therapy to treat HIV, people infected with the virus have been living longer and experiencing fewer of the medical conditions directly attributable to HIV infection and AIDS. However, with longer life expectancy, individuals living with long-term HIV infection exhibit many clinical characteristics commonly observed in aging: multiple chronic diseases or conditions, the use of multiple medications, and changes in physical and cognitive abilities.

The Medical Research Fellows Program enables students to be immersed in a high-impact, intensive research experience at a critical time in their professional education, before they make plans for residency or postdoctoral training. Unique aspects of the program include national and regional professional development activities, mentorship by physician-scientists, interaction with HHMI investigators, and integration into a community of like-minded peers. Each student selects and works with a mentor to develop a basic, translational, or applied biomedical research proposal. Both mentor selection and the research proposal are key components of the fellowship application; working with an HHMI scientist is encouraged but not required. Mentors can be at any academic or nonprofit research institution in the United States (excluding the National Institutes of Health and any other government agency) or at HHMI's Janelia Research Campus in Ashburn, VA. 

The Autism Science Foundation is inviting applications for its Pre- and Postdoctoral Training Awards from graduate students, medical students, and postdoctoral fellows interested in pursuing careers in basic and clinical research relevant to autism spectrum disorders. The proposed training must be scientifically linked to autism and may be broadened to include training in a closely related area of scientific research, including but not limited to human behavior across the lifespan (language, learning, behavior, communication, social function, motor skills & planning, epilepsy, sleep, repetitive disorders), neurobiology (anatomy, development, neuroimaging), pharmacology, neuropathology, genetics, epigenetics, genomics, epigenomics, immunology, molecular and cellular mechanisms, studies employing model organisms and systems, and studies of treatment and service delivery. Special consideration will be given to projects focused on gender issues in autism. This includes studies examining the female protective effect, neurobiological and neuroanatomical examination of the female autism brain, diagnostic differences and challenges in females, the female phenotype, and health and lifespan issues, including vocational services and employment. ASF also invites studies focused on unaffected siblings and recurrence risk in the offspring of unaffected siblings. ASF is also interested in supporting research on the neurobiology and molecular biology of autism using post-mortem brain tissue. The one-year awards include $25,000 for predoctoral and medical students and $35,000 for postdoctoral students.

The Dystonia Medical Research Foundation (DMRF) is seeking applications for collaborative studies exploring the role of torsinA in DYT1 dystonia that will address the most significant and immediate needs in this research area with special emphasis on cross-disciplinary research.

This FOA aims to elucidate basic sleep and circadian mechanisms contributing to the risk of opiate use disorder (OUD), the pathobiology of opiate withdrawal, and that influence the response to medication-assisted treatment (MAT). Studies are needed to apply advances in understanding sleep and circadian biology to improving our understanding of OUD, the directionality of sleep and OUD interactions, and the opportunities to improve therapy and outcome. Multi-disciplinary, multiple-investigator teams combining expertise in sleep and circadian neurobiology with the neurobiology OUD and pharmacology of MAT are strongly encouraged. This FOA is only open to the study of OUD relevant mechanisms and pathobiology. The study of other drugs of abuse will not be responsive.